68 results on '"Jonaitis, Erin M"'
Search Results
2. Synaptic density is correlated with Aβ plaques and neurofibrillary tau tangles across the clinical and biologic Alzheimer’s disease continuum
3. Longitudinal trajectories of myelin loss in the context of Alzhiemer’s disease biomarkers, glial activation, and APOE4
4. Plasma biomarkers as stand‐alone tests in the diagnosis of Alzheimer’s disease
5. Synaptic density is correlated with Aβ plaques and neurofibrillary tau tangles across the clinical and biologic Alzheimer’s disease continuum
6. The cerebrospinal fluid A‐T+ Alzheimer disease biomarker profile: prevalence and clinical relevance
7. Using Different Time Operationalizations To Investigate Relationships Among Amyloid PET, White Matter Hyperintensities, And Cognition In A Cognitively Unimpaired Sample
8. Longitudinal changes in blood flow, vessel pulsatility, and trans‐capillary pulse wave delay in small vessel disease and amyloid biomarker positive
9. Cluster analysis of the longitudinal progression of plasma biomarkers and amyloid imaging in the Wisconsin Registry for Alzheimer’s Prevention
10. Examining Complex Relationships among Cerebrovascular, β‐Amyloid, Tau and Cognitive Measures in a Cognitively Unimpaired Late‐Middle Aged Sample
11. Does amyloid moderate practice effects in language measures in a cognitively unimpaired at‐risk sample?
12. A study on the sample representativeness of the Wisconsin Alzheimer’s Disease Research Center Clinical Core participants versus the Wisconsin state population
13. Regional correlation analysis between neuronal metabolism and synaptic density using [18F]FDG and [11C]UCB‐J
14. Peripheral insulin resistance and creatinine levels are associated with plasma phosphorylated tau
15. CSF SNAP‐25 Correlations with Synaptic Density by [11C]‐UCB‐J‐PET Imaging and AD Biomarkers
16. Cluster analysis of the longitudinal progression of plasma biomarkers and amyloid imaging in the Wisconsin Registry for Alzheimer’s Prevention
17. Two novel cerebrospinal fluid markers for vascular injury are associated with CSF markers of AD, neurodegeneration, and gliosis
18. Regional correlation analysis between neuronal metabolism and synaptic density using [18F]FDG and [11C]UCB‐J
19. Plasma ALZpath p‐tau217 for the identification of amyloid and tau positivity
20. Longitudinal trajectories of myelin loss in the context of Alzhiemer’s disease biomarkers, glial activation, and APOE4
21. Large‐scale proteome and metabolome analysis of CSF implicates altered glucose and carbon metabolism and succinylcarnitine in Alzheimer's disease
22. Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi‐cohort study
23. An examination of baseline plasma Aβ42/40 and intra‐individual cognitive variability (IICV) associations with longitudinal cognitive change in a Black Cohort: Data from the African Americans Fighting Alzheimer’s in Midlife (AA‐FAIM) study
24. Associations between semantic memory for proper names in story recall and CSF amyloid and tau in a cognitively unimpaired sample
25. Assessing the Biological Mechanisms linking Smoking Behavior and Alzheimer’s Disease: Mediation Analysis of Metabolomic Data
26. The role of Cognitive Reserve and depression on executive functions in older adults: a 10‐year longitudinal study
27. Trajectories of cognitive performance in late middle‐aged adults: Bayesian random change point mixed model analysis in WRAP
28. Best combination of CSF biomarkers for predicting cognitive decline and clinical progression: A multi‐cohort study
29. Diabetes is related to cognition but not plasma amyloid‐β 42/40 in an African American cohort
30. Lower synaptic density and higher neurofibrillary tau are associated with worse cognitive performance
31. Apolipoprotein E moderates the association between Non‐ APOE Polygenic Risk Score for Alzheimer’s Disease and Aging on Preclinical Cognitive Function
32. Examining differences across cognitive trajectory profiles in late middle‐aged adults: Results from the Wisconsin Registry for Alzheimer’s Prevention
33. Mid‐to‐Late Life Healthy Lifestyle Modifies Genetic Risk for Longitudinal Cognitive Aging among Asymptomatic Individuals from the Wisconsin Registry for Alzheimer’s Prevention
34. Examining cerebrovascular burden across the cognitive continuum in older adults with and without evidence of amyloidosis
35. Gut microbe‐modulated metabolites are longitudinally associated with higher neurodegeneration biomarkers in cerebrospinal fluid (CSF)
36. Menopause age and hormone therapy use moderate PET tau and amyloid association: findings from the Wisconsin Registry for Alzheimer Prevention
37. Participant education and preparedness in learning personal β‐amyloid PET results: Preliminary findings from the Wisconsin Registry for Alzheimer’s Prevention
38. Amyloid duration and entorhinal tau interact to influence cognition in preclinical Alzheimer’s disease
39. Examining cerebrovascular burden across the cognitive continuum in older adults with and without evidence of amyloidosis
40. Factors related to willingness to participate in AD biomarker studies that disclose personal results
41. Telephone survey to identify factors predicting willingness to enroll in biomarker studies and disclosure‐related outcomes
42. Amyloid time: Quantifying the onset of abnormal biomarkers and cognitive impairment along the Alzheimer’s disease continuum
43. Age of amyloid onset, but not amyloid accumulation rate, differs across APOE‐e4 carriers vs. non‐carriers in three cohorts and three methods
44. CSF sphingomyelin metabolites in Alzheimer’s disease, neurodegeneration, and neuroinflammation
45. Amyloid status is associated with deficits in connected speech language
46. Association of anticholinergic medication and AD biomarkers among cognitively normal late middle‐age adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP)
47. Cardiorespiratory fitness mitigates brain atrophy and cognitive decline in preclinical Alzheimer’s disease
48. Examining differences across sleep profiles in late middle‐aged adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP)
49. CSF amyloid, tau, and neurodegeneration biomarkers are associated with longitudinal cognitive decline in preclinical AD
50. Age at menopause relates to later‐life hippocampal volume in an APOE4‐specific manner
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.